| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Generated third quarter revenue of $12.9 million, driven by expanded commercial organization and increasing market penetration |
| 22 Sep 2026 |
8-K: Other Events
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug DeliveryTM (PEDDTM) Portfolio for Liver Embolization |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration |
| 14 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2026, TriSalus Life Sciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
TriSalus Life Sciences Reports First Quarter 2026 Results Commercial and Clinical Progress for Facilitating Long-Term Growth |
| 29 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
WESTMINSTER, Colo. — April 7, 2026 — TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to tra... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53% , respectively, Versus the Prior Year Periods |
| 20 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As Representative of the several Underwriters named on Schedule A hereto |
| 09 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
WESTMINSTER, Colo. — February 9, 2026 — TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care thera... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth |
| 01 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. |
| 29 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Company delivers $11.2M in revenues resulting in 52% growth year-over-year and 22% growth quarter-over-quarter |
| 24 Jul 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
This Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock (the “Amendment”) is dated as of July 24, 2025. |
| 23 Jun 2025 |
8-K: Other Events
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure |
| 16 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, TriSalus Life Sciences, Inc. (the “Company”) held its Annual Meeting of Shareholders (the “Meeting”). |
| 30 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
This Agreement and Release ("Agreement") is made by and between TriSalus Life Sciences, Inc. (the "Company"), and James Young (the "Executive") (collectively referred to herein as the "Parties" and each a "Party"). Capitalized terms used... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement |
Loading...